Cell News and Research

RSS

Genentech announces Phase II RG7204 clinical study results for metastatic melanoma tumors

Genentech, Inc., a member of the Roche Group today announced results from a Phase II clinical study of RG7204 (PLX4032), an investigational first-in-class molecule designed to selectively inhibit a cancer-causing, mutated form of the BRAF protein found in approximately half of metastatic melanoma tumors.

8 Nov 2010

Researchers identify gene linked to melanoma metastasis

Researchers at Washington University School of Medicine in St. Louis have identified a gene linked to the spread of eye melanoma.

8 Nov 2010

Research uncovers mechanism that may help develop new strategies for osteoporosis treatment

Osteoporosis, a condition characterized by weak and fragile bones, develops when there is an imbalance in the remodeling process and more bone is lost than replaced. Now, new research published by Cell Press in the November issue of the journal Cell Stem Cell uncovers a mechanism that may guide development of better strategies for treatment osteoporosis.

8 Nov 2010

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented positive preliminary data from fully monitored study data for the entire study population of 80 subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma.

8 Nov 2010

Skin to blood transformation in the lab

In a new study scientists have successfully transformed human skin cells into blood without first being sent through a primordial, stem-cell-like state. The findings were published online in the journal Nature. Earlier work has shown that fibroblast cells from mouse skin, treated with the right cocktail of chemicals, can be transformed into neurons and heart muscle. This is a first with human cells.

7 Nov 2010

Scientists discover new way to create human blood from adult skin

In an important breakthrough, scientists at McMaster University have discovered how to make human blood from adult human skin. The discovery, published in the prestigious science journal Nature today, could mean that in the foreseeable future people needing blood for surgery, cancer treatment or treatment of other blood conditions like anemia will be able to have blood created from a patch of their own skin to provide transfusions.

7 Nov 2010

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.

4 Nov 2010

Rockwell Medical third quarter sales increases 4.1% to $14.7 million

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported third quarter 2010 results today.

4 Nov 2010

CaPre drug candidate effective in managing impaired glucose tolerance

Neptune Technologies & Bioressources Inc. subsidiary Acasti Pharma Inc. reports preclinical results showing that its leading drug candidate CaPre, performed significantly better than the currently marketed drug, Lovaza, at managing impaired glucose tolerance (IGT) a serious pre-diabetic state associated with increased risk of diabetes and heart disease.

4 Nov 2010

Athersys secures three Therapeutic Discovery Project grants

Athersys, Inc. announced today that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem® for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation.

4 Nov 2010

Undamaged portions of brain 'take over' and support recovery of function: Study

New research provides fascinating insight into mechanisms that underlie recovery after damage to a region of the brain important for memory and attention. The research, published by Cell Press in the November 4th issue of the journal Neuron, highlights the role of undamaged portions of the brain that can "take over" and support the recovery of function.

4 Nov 2010

NWBT receives $490,000 in two grants under QTDP program

Northwest Biotherapeutics today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants.

4 Nov 2010

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments.

4 Nov 2010

NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues and organs, today announced that OXY111A, its clinical stage candidate for the treatment of chronic heart failure and cancer, has been selected as one of Windover's "Top 10 Cardiovascular/Metabolic Projects to Watch."

4 Nov 2010

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that data from a phase I single-agent clinical trial of brentuximab vedotin (SGN-35) will be published in the November 4, 2010 issue of the New England Journal of Medicine.

4 Nov 2010

Frequent long-term use of cell phones may increase cancer risk

Public health concerns have been raised today about the safety of being exposed to radiofrequency (RF) radiation emitted from cell phones. A report released by the Ontario Agency for Health Protection and Promotion (OAHPP) in September 2010 was one of the studies cited as providing evidence that frequent long-term use of cell phones may be associated with an increased risk of cancer.

4 Nov 2010

Early interference in entorhinal cortex may halt progression of Alzheimer's disease

New research is helping to unravel the events that underlie the "spread" of Alzheimer's disease (AD) throughout the brain. The research, published by Cell Press in the November 4th issue of the journal Neuron, follows disease progression from a vulnerable brain region that is affected early in the disease to interconnected brain regions that are affected in later stages. The findings may contribute to design of therapeutic interventions as targeting the brain region where AD originates would be simpler than targeting multiple brain areas.

4 Nov 2010

Beginner's guide to cancer

An academic from The University of Nottingham has written the first introductory guide to cancer, covering everything from the biology of the disease and why some people are more at risk of developing it than others, to the latest research into prevention, treatment and cure.

4 Nov 2010

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

"For brain cancer patients after surgery, the combined DC-CIK and stem cell therapy from Cellonis Biotechnologies can be a very effective method in preventing cancer recurrence," says renowned cancer doctor Dr. Dinggang Li.

4 Nov 2010

Lentigen awarded $1.23M grant under Patient Protection and Affordable Care Act

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that it will receive $1,235,306 in cash grants from the U.S. Government under the Patient Protection and Affordable Care Act.

4 Nov 2010

Cell News and Research

Genentech announces Phase II RG7204 clinical study results for metastatic melanoma tumors

Researchers identify gene linked to melanoma metastasis

Research uncovers mechanism that may help develop new strategies for osteoporosis treatment

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Skin to blood transformation in the lab

Scientists discover new way to create human blood from adult skin

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Rockwell Medical third quarter sales increases 4.1% to $14.7 million

CaPre drug candidate effective in managing impaired glucose tolerance

Athersys secures three Therapeutic Discovery Project grants

Undamaged portions of brain 'take over' and support recovery of function: Study

NWBT receives $490,000 in two grants under QTDP program

AVEO third quarter total collaboration revenues increase to $6.2 million

NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

Frequent long-term use of cell phones may increase cancer risk

Early interference in entorhinal cortex may halt progression of Alzheimer's disease

Beginner's guide to cancer

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

Lentigen awarded $1.23M grant under Patient Protection and Affordable Care Act

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News